Improvements in medical interventions and living conditions have dramatically increased the average human lifespan over the last century. As a result, emotional and cognitive fitness has become a major determinant, and unmet challenge, to the quality of life during old age. Indeed, if successful aging is achievable, for numerous individuals, low mood is too often an early symptom and significant contributor to the downward spiral of aging, which includes further cognitive and motor declines. Low mood is also observed in presymptomatic stages of neurodegenerative disorders, together suggesting that mood regulation may be selectively vulnerable at the vigor-to-frailty transition. However, this hypothesis has been difficult to test, as correlations between molecular changes and functional declines are logistically complex to assess in elderly individuals, and, since means to identify individuals at higher biological risk are not available. Here, we propose to identify "genetic modulators" that associate with both biological and functional aging, by performing parallel postmortem and in vivo studies. Our assay for biological aging is based on the fact that brain aging associates with robust molecular, cellular and structural changes, for which we have identified a specific set of genes with age-dependent expression changes. This "molecular signature" of aging contains many neuropsychiatric and neurodegenerative disease-related genes, which are affected in disease-promoting directions, suggesting that aging may promote aspects of diseases. Notably, we show that molecular age - defined herein as the age that is predicted by the gene expression profile in that individual - can deviate from chronological age. For instance, individuals carrying a DNA variant in a putative longevity gene (Sirtuin 5) display older molecular ages, potentially through accelerated age-dependent declines in mitochondrial-related gene transcripts. Thus, we hypothesize that subjects carrying "risk" alleles associated with older brain molecular age will display higher incidence of mood and other low function symptoms, and conversely that subjects carrying "protective" alleles may experience greater successful aging. To test this hypothesis, we will systematically identify genetic variants associated with older or younger brain molecular ages in postmortem individuals (n~300) (Aim 1). We will then assess the extent to which the presence of these identified "risk" or "protective" genetic factors predicts corresponding functional outcomes in vivo in elderly individuals, as manifested by mood, cognitive and motor age-dependent changes in subjects from two epidemiological studies of aging: the Cardiovascular Health (n=5,888) and Health Aging and Body Composition (n=3,075) studies (Aim 2). At the end of this study, we will have achieved (i) the identification of robust genetic markers for biological and functional aging, and (ii) a more detailed characterization of biological/functional links between mood, cognition and motor functions. This will provide (iii) evidence-based hypotheses to monitor critical functional domains in old age, and (iv) biological leads for rational experimental design to investigate successful aging.

Public Health Relevance

The number of individuals reaching the age of 65 in the United States rose three-fold in the 20th century, and may reach above 20% by the middle of this century. Along with the increase in life expectancy comes increased risk for the development of neuropsychiatric and neurodegenerative disorders of late life. Nonetheless, while some dysfunction appears inevitable, successful physical, emotional and cognitive aging is achievable, suggesting that biological mechanisms relating to aging can be slowed down under certain circumstances, and/or that protective mechanisms may be recruited throughout the lifespan. Therefore, it is now becoming imperative to identify markers (and associated biological functions) for age-dependent negative outcomes, so that we can identify individuals at risk, investigate relevant mechanisms, and develop approaches to prevent or delay functional declines and associated disorders in mid-life and elderly individuals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH093723-04
Application #
8617301
Study Section
Pathophysiological Basis of Mental Disorders and Addictions Study Section (PMDA)
Program Officer
Evans, Jovier D
Project Start
2011-05-13
Project End
2016-02-29
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
4
Fiscal Year
2014
Total Cost
$507,725
Indirect Cost
$114,756
Name
University of Pittsburgh
Department
Psychiatry
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213